Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins

Executive Summary

MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.

You may also be interested in...



Immunocore To Tap Into HTA Advice To Ensure IMCgp100 Success

British immunotherapy specialist Immunocore plans to make full use of the scientific advice European HTAs are offering to help it progress its lead product IMCgp100 through the European Medicines Agency's Adaptive Pathways pilot program.

MHRA’s Rawlins Plans British Version Of FDA’s Reg Science Centers

The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.

MHRA’s Rawlins Plans British Version Of FDA’s Reg Science Centers

The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel